A recent observational study published in the “Journal of Clinical Medicine” reveals that sublingual immunotherapy (SLIT) is not only effective but also remarkably safe in the treatment of tree pollen allergies. This study was conducted by a team led by renowned researcher Christoph Owenier which spanned over eight months and involved 432 patients with moderate-to-severe seasonal allergic rhinitis/rhinoconjunctivitis across 84 sites in Germany.

It was intended to examine the safety and tolerability of 2 sublingual tree pollen extracts authorized in 2018. This prospective, non-interventional study (NIS) found that both sublingual liquid allergen extracts of birch pollen (SBPE) and a combination of birch, hazel plus alder tree pollen (STPE) were incredibly well-tolerated by patients. A minimum of one local reaction appeared in 22.2% of patients, comparatively fewer patients (6.3%) had systemic reactions.

Interestingly, the study noted that STPE-treated patients had more frequent systemic reactions than SBPE-treated patients, with just 1 patient encountering a systemic grade 3 hypersenstivity reaction. Fortunately, severe reactions were not witnessed. As found, 98.6% of people who accomplished all visits expressed their satisfaction with SLIT. In fact, 71% of patients completed all visits, showcasing a high level of patient compliance.

What's truly remarkable is that the incidence of adverse events was significantly lower in this NIS than the clinical phase III study data.